What SEC filings does AbCellera Biologics Inc. submit to the SEC?

AbCellera Biologics Inc. (ABCL) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ABCL?

A Form 4 for ABCL discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from AbCellera Biologics Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ABCL?

The 10-K is AbCellera Biologics Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ABCL SEC filings directly on EDGAR?

You can view all historical AbCellera Biologics Inc. filings on the SEC EDGAR company page for ABCL. Each filing card on this page links directly to the original SEC document.

How often does AbCellera Biologics Inc. file with the SEC?

AbCellera Biologics Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ABCL shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ABCL SEC Filing News — AbCellera Biologics Inc.

Latest SEC filings for AbCellera Biologics Inc. (ABCL) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-24.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc…

Sector: Healthcare Industry: Biotechnology Market Cap: $3.8B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ABCL currently lean bullish. Of the 20 displayed SEC filing records, 4 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 10 insider transactions (Form 4) in this period.

ABCL Filing Activity Snapshot 2026-06-05 — 2026-08-24

Insider Transactions (Form 4)

4 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$570.4K

Hayden Michael R (Director) · 2026-08-24

53,613 shares · Form 4

Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for AbCellera Biologics Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 5 compensation award, 4 open-market purchase and 1 gift. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×5: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×4: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Open-market purchase Insider Buying 2026-08-24

ABCL insider Hayden Michael R (Director) bought 53,613 shares (~$570.4K)

Hayden Michael R, listed as Director at AbCellera Biologics Inc., reported an open-market purchase of 53,613 ABCL shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	53,613	$10.64	$570.4K

Filing: Form 4 (Insider Transaction) Insider: Hayden Michael R (Director) Shares: 53,613 Est. Value: $570.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-18

ABCL insider Montalbano John S. (Director) bought 10,000 shares (~$110.3K)

Montalbano John S., listed as Director at AbCellera Biologics Inc., reported an open-market purchase of 10,000 ABCL shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	10,000	$11.03	$110.3K

Filing: Form 4 (Insider Transaction) Insider: Montalbano John S. (Director) Shares: 10,000 Est. Value: $110.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-14

ABCL insider Booth Andrew (Chief Financial Officer) bought 37,200 shares (~$383.9K)

Booth Andrew, listed as Chief Financial Officer at AbCellera Biologics Inc., reported an open-market purchase of 37,200 ABCL shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	37,200	$10.32	$383.9K

Filing: Form 4 (Insider Transaction) Insider: Booth Andrew (Chief Financial Officer) Shares: 37,200 Est. Value: $383.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-14

ABCL insider Hayden Michael R (Director) bought 46,387 shares (~$481.0K)

Hayden Michael R, listed as Director at AbCellera Biologics Inc., reported an open-market purchase of 46,387 ABCL shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	46,387	$10.37	$481.0K

Filing: Form 4 (Insider Transaction) Insider: Hayden Michael R (Director) Shares: 46,387 Est. Value: $481.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-08-13

ABCL insider Form 4 filed for equity award, exercise, or tax withholding

Hayden Michael R (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	50,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Hayden Michael R (Director) Shares: 50,000

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-06

ABCL insider Form 4 filed for equity award, exercise, or tax withholding

Seely Lynn (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share option (right to buy)	152,207	—	—

Filing: Form 4 (Insider Transaction) Insider: Seely Lynn (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-06

ABCL insider Form 4 filed for equity award, exercise, or tax withholding

Sandor Victor (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share option (right to buy)	152,207	—	—

Filing: Form 4 (Insider Transaction) Insider: Sandor Victor (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

ABCL insider Form 4 filed for equity award, exercise, or tax withholding

Hayden Michael R (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share option (right to buy)	111,701	—	—

Filing: Form 4 (Insider Transaction) Insider: Hayden Michael R (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

ABCL insider Form 4 filed for equity award, exercise, or tax withholding

Quake Stephen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share option (right to buy)	111,701	—	—

Filing: Form 4 (Insider Transaction) Insider: Quake Stephen (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-12

ABCL insider Form 4 filed for equity award, exercise, or tax withholding

Montalbano John S. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Share option (right to buy)	111,701	—	—

Filing: Form 4 (Insider Transaction) Insider: Montalbano John S. (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for AbCellera Biologics Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-13